广州医药 ›› 2016, Vol. 47 ›› Issue (3): 26-27.DOI: 10.3969/j.issn.1000-8535.2016.03.009

• 论著 • 上一篇    下一篇

同步放化疗治疗晚期非小细胞肺癌的疗效观察

张英燕, 曾建芳, 罗秀玉   

  1. 广东省梅州市人民医院化疗一科(梅州 514000)
  • 收稿日期:2016-03-02 出版日期:2016-05-20 发布日期:2021-11-30
  • 通讯作者: 张英燕,E-mail:kdxxchenzy@163.com

Efficacy of concurrent radiotherapy and chemotherapy in the treatment of advanced non small cell lung cancer

Zhang Yingyan, Zeng Jianfang, Luo Xiuyu   

  1. Department of Chemotherapy, Meizhou People's Hospital, Meizhou 514000, China
  • Received:2016-03-02 Online:2016-05-20 Published:2021-11-30

摘要: 目的 探讨同步放化疗治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法 选取我院2014年收治的晚期NSCLC患者102例,随机分为观察组和对照组,对照组以紫杉醇联合顺铂化疗方案(TP)化疗治疗,观察组加用三维适形放疗同步放化疗治疗,观察两组的临床疗效和不良反应。结果 观察组和对照组患者的总有效率分别为43.14%和21.57% (P<0.05),两组患者的总控制率分别为84.31%和66.67% (P<0.05)。两组患者Ⅲ~Ⅳ级胃肠道反应、白细胞减少、骨髓抑制的发生率差异无统计学意义(P>0.05),观察组比对照组增加了放射性肺炎和放射性食管炎的发生 (P<0.05)。两组患者生活质量比较,差异具有统计学意义(P<0.05)。结论 同步放化疗治疗晚期NSCLC可以显著提高治疗的总有效率、肿瘤的控制率及生活质量,但也使不良反应增加,选择治疗方案时应根据个体情况综合考虑。

关键词: 同步放化疗, 晚期非小细胞肺癌, 疗效

Abstract: Objective To study the clinical efficacy of concurrent chemoradiotherapy in the treatment of advanced non small cell lung cancer (NSCLC). Methods 102 cases of advanced NSCLC treated in our hospital in 2014 were selected and randomly divided into the observation group and the control group. Patients in control group were treated by chemotherapy with Paclitaxel combined Cisplatin (TP), while those in observation group were treated by concurrent chemoradiotherapy with three- dimensional conformal radiotherapy and TP. The clinical efficacy and adverse reactions of the two groups were observed. Results The total effective rate of the observation group and the control group were 43.14% and 21.57% (P<0.05), respectively. The total control rate of the two groups were 84.31% and 66.67%(P<0.05). In two groups III ~ IV gastrointestinal tract reaction, leukopenia, bone marrow suppression occurrence had no statistical significance(P>0.05). Incidence of radiation pneumonitis and radiation esophagitis increased in observation group(P<0.05). The difference of quality of life between the two groups was statistically significant(P<0.05). Conclusion Concurrent radiotherapy and chemotherapy in the treatment ofadvanced non-small cell lung cancer(NSCLC)can not only significantly improve the treatment, tumor control rate and quality of life, but also make adverse reaction increased. Treatment options should be chosen based on individual circumstances into account

Key words: Concurrent chemoradiotherapy, Advanced non small cell lung cancer, Efficacy